Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target

Tsun Yee Tsang; Wei Wei; Hiroaki Itamochi; Rosemary Tambouret; Michael J. Birrer

doi:10.18632/oncotarget.19946

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Priority Research Papers:

Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target

Tsun Yee Tsang, Wei Wei, Hiroaki Itamochi, Rosemary Tambouret and Michael J. Birrer _

PDF | HTML | Supplementary Files | How to cite | Podcast

Oncotarget. 2017; 8:96482-96495. https://doi.org/10.18632/oncotarget.19946

Metrics: PDF 1958 views | HTML 2898 views | ?

Abstract

Tsun Yee Tsang1,2, Wei Wei1,2, Hiroaki Itamochi3, Rosemary Tambouret1 and Michael J. Birrer1,2

1 Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

2 Harvard Medical School, Boston, Massachusetts, USA

3 Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Tottori, Japan

Correspondence to:

Michael J. Birrer, email:

Keywords: clear cell ovarian cancer, PRKCI, genomics, microarray, therapeutic target

Received: April 07, 2017 Accepted: May 29, 2017 Published: August 04, 2017

Abstract

Clear cell ovarian cancer (CCOC) is an epithelial ovarian cancer histotype with unique pathologic, biologic and clinical features. Despite its worse prognosis than serous ovarian cancer (SOC), the genomic landscape of CCOC is less well defined. Integrated genomic analysis of CCOC allows the identification of potential therapeutic targets to improve the treatment of this tumor. Using comparative genomic hybridization and gene expression profiling, we have screened 12 CCOC cell lines and 40 tumors to identify 45 amplified and overexpressed genes. Pathways analysis of these genes identified 19 genes with cancer-related functions. Of these, PRKCI is one of the most frequently amplified and overexpressed genes and its expression induced cancer cell proliferation and migration/invasion in vitro as well as tumor growth in vivo. Targeting PRKCI by small molecule inhibitor, sodium aurothiomalate (ATM), significantly reduced the in vivo tumor growth and may be a new therapeutic strategy to improve the treatment of CCOC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19946

Publication Alerts

Priority Research Papers:

Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target

Abstract